3 results match your criteria: "Davis VA Medical Center[Affiliation]"

miRNA: The Next Frontier in Dermatology Research and Therapeutics.

Indian J Dermatol

October 2024

Department of Dermatology, Rheumatology and Immunology, University of California, Davis VA Medical Center, Sacramento, California, USA.

Engagement of microribonucleic acids (miRNA) in the regulation of cutaneous cellular health and diseases is a rapidly advancing niche in dermatology basic research. miRNAs have been identified to play a key role in the pathogenesis of various cutaneous inflammatory, autoimmune and neoplastic conditions, among others. In addition, their purported role as therapeutic targets and biomarkers in diseased conditions harbours exciting news for the approaching years in clinical research.

View Article and Find Full Text PDF

Functional role of IL-22 in psoriatic arthritis.

Arthritis Res Ther

March 2012

University of California, Davis, School of Medicine, Dermatology, Davis & VA Medical Center Sacramento, Mather, CA, USA.

Introduction: Interleukin-22 (IL-22) is a cytokine of IL-10 family with significant proliferative effect on different cell lines. Immunopathological role of IL-22 has been studied in rheumatoid arthritis (RA) and psoriasis. Here we are reporting the functional role of IL-22 in the inflammatory and proliferative cascades of psoriatic arthritis (PsA).

View Article and Find Full Text PDF

Progress in the control of acute and delayed emesis induced by cisplatin.

Eur J Cancer

October 1991

Division of Haematology-Oncology, Davis/VA Medical Center, California.

Ondansetron, a new 5-HT3 receptor antagonist, has been compared with high-dose metoclopramide in the control of acute emesis (24 h) induced by cisplatin (greater than or equal to 100 mg/m2). Ondansetron, given as three intravenous doses (0.15 mg/kg) 4-hourly, was superior to six intravenous doses of metoclopramide (2.

View Article and Find Full Text PDF